AU2023262720A1 - Inhibitors of rock2 - Google Patents

Inhibitors of rock2 Download PDF

Info

Publication number
AU2023262720A1
AU2023262720A1 AU2023262720A AU2023262720A AU2023262720A1 AU 2023262720 A1 AU2023262720 A1 AU 2023262720A1 AU 2023262720 A AU2023262720 A AU 2023262720A AU 2023262720 A AU2023262720 A AU 2023262720A AU 2023262720 A1 AU2023262720 A1 AU 2023262720A1
Authority
AU
Australia
Prior art keywords
alkyl
group
alkynyl
alkenyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023262720A
Other languages
English (en)
Inventor
Dominik Domagała
Anna Jędrzejczak
Georgiy KACHKOVSKYI
Martin KLVAŇA
Magdalena SOLUCH
Samuel D. Waksal
Alexandra Zanin-Zhorov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Graviton Bioscience BV
Original Assignee
Graviton Bioscience BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Graviton Bioscience BV filed Critical Graviton Bioscience BV
Publication of AU2023262720A1 publication Critical patent/AU2023262720A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2023262720A 2022-04-29 2023-04-29 Inhibitors of rock2 Pending AU2023262720A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263336667P 2022-04-29 2022-04-29
US63/336,667 2022-04-29
PCT/IB2023/054494 WO2023209692A1 (en) 2022-04-29 2023-04-29 Inhibitors of rock2

Publications (1)

Publication Number Publication Date
AU2023262720A1 true AU2023262720A1 (en) 2024-12-12

Family

ID=86604437

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023262720A Pending AU2023262720A1 (en) 2022-04-29 2023-04-29 Inhibitors of rock2

Country Status (9)

Country Link
US (1) US20250289807A1 (cg-RX-API-DMAC7.html)
EP (1) EP4514466A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025514382A (cg-RX-API-DMAC7.html)
KR (1) KR20250019030A (cg-RX-API-DMAC7.html)
CN (1) CN119604496A (cg-RX-API-DMAC7.html)
AU (1) AU2023262720A1 (cg-RX-API-DMAC7.html)
CA (1) CA3250707A1 (cg-RX-API-DMAC7.html)
IL (1) IL316616A (cg-RX-API-DMAC7.html)
WO (1) WO2023209692A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026502949A (ja) 2022-12-30 2026-01-27 アヴィセンナ バイオサイエンシズ インコーポレイテッド アザインドールrock阻害剤
IL327381A (en) 2023-09-28 2026-05-01 Graviton Pharmaceuticals B V Treatment for type 1 diabetes using ROCK2 and DYRK1 inhibitors
IL327385A (en) 2023-09-29 2026-05-01 Graviton Pharmaceuticals B V ROCK2 inhibitors in the treatment of obesity
WO2026011129A1 (en) * 2024-07-03 2026-01-08 Avicenna Biosciences, Inc. Azaindole rock inhibitors for the treatment of medical disorders
CN120204259B (zh) * 2025-04-17 2025-11-18 江西省肿瘤医院(江西省第二人民医院、江西省癌症中心) Rock2抑制剂及其在制备治疗胆管癌的药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7311228B2 (ja) 2017-06-30 2023-07-19 ベイジン タイド ファーマシューティカル カンパニー リミテッド Rho-関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用
JP7399848B2 (ja) * 2017-09-01 2023-12-18 カドモン コーポレイション,リミティド ライアビリティ カンパニー Rho関連コイルドコイル含有プロテインキナーゼの阻害剤

Also Published As

Publication number Publication date
WO2023209692A1 (en) 2023-11-02
CN119604496A (zh) 2025-03-11
JP2025514382A (ja) 2025-05-02
KR20250019030A (ko) 2025-02-07
US20250289807A1 (en) 2025-09-18
CA3250707A1 (en) 2023-11-02
IL316616A (en) 2024-12-01
EP4514466A1 (en) 2025-03-05

Similar Documents

Publication Publication Date Title
US20250289807A1 (en) Inhibitors of ROCK2
EP4622973A1 (en) Inhibitors of rock2
AU2018222073B2 (en) O-aminoheteroaryl alkynyl-containing compound, preparation method therefor, and use thereof
WO2024193439A1 (zh) Shp2磷酸酶变构抑制剂
EP2978752B1 (en) 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors
CN117143107A (zh) 1,2-二氢吡啶类衍生物及其制备方法和用途
JP2020532549A (ja) Rho関連コイルドコイル含有プロテインキナーゼの阻害剤
US10472349B2 (en) Salt of pyridinyl amino pyrimidine derivative, preparation method therefor, and application thereof
AU2012328167A1 (en) New compounds
EP3418277B1 (en) Substituted amino six-membered nitric heterocyclic ring compound and preparation and use thereof
KR20240150493A (ko) 화합물 및 그 용도
AU2024208947A1 (en) Prmt5-mta inhibitor
CN114599655B (zh) 咪唑烷酮类化合物及其制备方法与应用
KR20260023568A (ko) Enpp1 억제제의 결정형
CN120457116A (zh) Shp2抑制剂、组合物及其制备方法
KR20250051688A (ko) TGF-β 억제제 화합물 및 그 사용
AU2023366352A1 (en) New inhibitors of phosphatidylinositol 3-kinase
CN111377906B (zh) 取代的吡嗪化合物及其制备方法和用途
WO2025119352A1 (zh) 一种并环类mat2a抑制剂、包含其的药物组合物及其应用
JP2021523194A (ja) インドリン−1−カルボキサミド化合物、そのための調製方法及びその医学的使用
HK1217701B (en) 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors